1. Swedres 2007
Figures and tables
Swedres 2007

2. Table 3.1.1. Total sales of antibacterial drugs for systemic use in Sweden 2000-2007, DDD/1000/day.
Methenamine is an antiseptic and therefore of no interest regarding antibiotic resistance, even though the WHO Collaborating Centre for Drug Statistics methodology classifies it as an antibacterial drug.
Swedres 2007

3. Figure 3.1.1. Antibiotics in community care, DDD/1000/day, with and without methenamine.
Swedres 2007

4. Figure 3.1.2. Antibiotics in community care 2007, percent of total DDD/1000/day.
*Methenamine represents more than 99% of the group ”Other antibacterials”.
Swedres 2007

5. Figure 3.1.3. Antibiotics in community care 2005-2007, DDD/1000/day.
*Methenamine use represents more than 99% of the group ”Other antibacterials”.
Swedres 2007

6. Figure Antibiotic use in community care in the 21 counties of Sweden. Prescriptions/1000/year, , J01 excl methenamine.
Swedres 2007

7. Figure Fraction of the population treated with at least one course of antibiotics (J01 excl methenamine) in community care in 2007.
The 21 counties of Sweden, all ages, users/1000 inhabitants. Age and gender standardized data.
Swedres 2007

8. Figure Sales of antibiotics (J01 excl methenamine) in the 21 counties of Sweden Children aged 0-6 years, community care, prescriptions/1000/year.
Swedres 2007

9. Figure Fraction of the population treated with at least one course of antibiotics (J01 excl methenamine) in comunity care in 2007.
The 21 counties of Sweden, children aged 0-6 years, users/1000/children.
Swedres 2007

10. Figure Swedish municipalities with the highest and lowest fraction of children treated with at least one course of antibiotics (J01 excl methenamine) in community care in Children aged 0-6 years, users/1000. Red coloured municipalities are large in size, yellow coloured are of medium size and blue coloured are small municipalities.
Swedres 2007

11. Figure Antibiotics commonly used for respiratory tract infections. Prescriptions/1000/year, community care,
Swedres 2007

12. Figure Antibiotics commonly used for respiratory tract infections, community care DDD/1000/day, age and gender standardized data.
Swedres 2007

13. Figure Antibiotics commonly used for urinary tract infections. Women aged 18 years or older, , prescriptions/1000/year.
Swedres 2007

14. Table 3.1.2. Antibiotic use in hospital care, 2000-2007, DDD/1000/day.
Swedres 2007

15. Figure 3.1.12. Antibiotics in hospital care 2007, percent of total DDD/1000/day.
*Methenamine represents more than 98% of the group ”Other antibacterials”.
Swedres 2007

16. Figure 3.1.13. Antibiotics in hospital care 2005-2007, DDD/1000/day.
Swedres 2007

17. Figure Tetracyclines (J01AA) in hospital care, all counties of Sweden , DDD/1000 inhabitants.
Swedres 2007

18. Figure Incidence of genital Chlamydia, all counties of Sweden , number of cases/1000 inhabitants. Sorted as figure
Swedres 2007

19. Table 3. 1. 4. Antibiotics in hospital care 1997-2006
Table Antibiotics in hospital care DDD/100 admissions.
Swedres 2007

20. Table 3. 1. 5. Antibiotics in hospital care 1997-2006
Table Antibiotics in hospital care DDD/100 patient-days.
Swedres 2007

21. Figure Cephalosporins (J01DB-DE) in hospital care, all counties , DDD/100 patient-days.
Denominator data for 2006 is also used for 2007.
Swedres 2007

22. Figure Cephalosporins in hospital care, all counties 2007 (denominator data from 2006), DDD/100 patient-days.
Swedres 2007

23. Figure 3.1.18. Carbapenems (J01DH) in hospital care, all counties 2005-2007, DDD/100 patient-days.
Denominator data for 2006 is also used for 2007.
Swedres 2007

24. Figure Total community antibiotic use (methenamine excluded) in some European countries, DDD/1000/day. Source: ESAC
Swedres 2007

25. Table 3.1.6. Number of reports to the Swedish Medical Products Agency 2003-2007.
Swedres 2007

26. Table Number of most frequently reported spontaneously reported adverse events for fluoroquinolones and nitrofurantoin during the period
Swedres 2007

27. Figure 3.2.1. Use of antifungals in hospital care, 2000-2007.
Swedres 2007

28. Figure 4.1.1. Annual number of recorded screening samples 2001-2007.
Swedres 2007

29. Figure 4.1.2. Number of MRSA notified anually by country of acquisition, Sweden 2000-2007.
Domestic/Imported and Imported/Domestic means both alternatives possible, given in that order.
Swedres 2007

30. Table 4.1.1. MRSA notified in 2000-2007 by county under the Communicable Disease Act.
Swedres 2007

31. Figure 4.1.3. Age distribution of notified domestic cases of MRSA, Sweden 2000-2007.
Swedres 2007

32. Figure 4.1.4. The culture indication for domestic and imported MRSA cases in Sweden 2006-2007.
Swedres 2007

33. Figure 4.1.5. Source of MRSA acquisition by country of infection, Sweden 2006-2007.
Swedres 2007

34. Table Numbers and rates of resistance (%) to indicated antibiotics among MRSA strains
Swedres 2007

35. Figure 4. 1. 6. Resistance rates for S
Figure Resistance rates for S. aureus (data from the annual RSQC programme, approximately 3000 isolates per year).
*In 2005 resistance rates were recorded in S. aureus isolated from wounds and secretions from elderly people (>65 years).
Swedres 2007

36. Table S. aureus susceptibility results (number of strains and percentage) using the disk diffusion method and confirmation of the mecA gene according to SRGA in Sweden. Data reported from SMI to EARSS.
Swedres 2007

37. Figure 4. 1. 7. Number of PNSP cases and annual incidence of S
Figure Number of PNSP cases and annual incidence of S. pneumoniae with reduced susceptibility to penicillin, MIC> 0.5 mg/L) in Sweden
Swedres 2007

38. Figure 4.1.8. Age distribution of all cases reported with PNSP in Sweden 1997-2007.
Swedres 2007

39. Figure 4. 1. 9. Resistance rates for S
Figure Resistance rates for S. pneumoniae (data from the annual RSQC programme, approximately 3000 isolates per year).
Swedres 2007

40. Table 4.1.4. Invasive isolates of S. pneumoniae reported to EARSS.
Swedres 2007

41. Table 4. 1. 5. Resistance in invasive isolates of E
Table Resistance in invasive isolates of E. faecalis reported to EARSS
Swedres 2007

42. Table 4. 1. 6. Resistance in invasive isolates of E
Table Resistance in invasive isolates of E. faecium reported to EARSS
Swedres 2007

43. Figure Resistance rates (resistant isolates in percent of all S. pyogenes isolates) for three groups of antibiotics
Swedres 2007

44. Figure 4.1.11. The incidence of ESBL in Swedish counties.
Swedres 2007

45. Figure 4.1.12.a. Age and gender distribution of E. coli cases.
Swedres 2007

46. Figure 4.1.12.b. Age and gender distribution of K. pneumoniae cases.
Swedres 2007

47. Figure Resistance rates (resistant isolates in percent of all E. coli isolates) for six antibiotics
*Between fluoroquinolone resistance was detected with Norfloxacin, from 2002 with Nalidixic acid.
Swedres 2007

48. Table 4.1.7. E. coli from blood cultures in Sweden 2001-2007, reported to EARSS.
Swedres 2007

49. Figure Resistance rates (resistant isolates in percent of all K. pneumoniae isolates) for four groups of antibiotics
Swedres 2007

50. Table 4.1.8. K. pneumoniae from blood cultures in Sweden 2005-2007, reported to EARSS.
Swedres 2007

51. Figure Resistance rates (resistant isolates in percent of all P. aeruginosa isolates) for four groups of antibiotics
Swedres 2007

52. Table 4.1.9. P. aeruginosa from blood cultures in Sweden 2005-2007, reported to EARSS.
Swedres 2007

53. Table 4.1.10. H. pylori University Hospitel MAS, Malmö, Sweden 2001-2007.
Swedres 2007

54. Table 4.1.11. C. jejuni/coli University Hospitel MAS, Malmö, Sweden 2001-2007.
Swedres 2007

55. Table Antibiotic resistance rates (%) and β-lactamase production of Swedish N. gonorrhoeae strains from
Swedres 2007

56. Table 4. 1. 13. Drug resistant tuberculosis in Sweden
Table Drug resistant tuberculosis in Sweden. Resistance among initial isolates of M. tuberculosis or africanum to at least one of the four drugs: isoniazid, rifampicin, ethambutol or pyrazinamide.
Swedres 2007